Reduce Patient Risk of Transfusion-Associated Sepsis

According to the FDA, platelet components are uniquely vulnerable to bacterial outgrowth because of their room temperature storage and are associated with a higher risk of sepsis and related fatality than other transfusible components¹.

• Conventional platelets are susceptible to bacterial contamination
• Room temperature storage facilitates bacterial growth
  • Sensitivity of primary culture is only 26-44%^1-3
  • Utility of secondary testing is constrained by its limit of detection⁴
• Sepsis and bacterial infections attributed to platelets are underrepresented due to passive reporting⁵
• Hospital-acquired infections are associated with platelet transfusions⁶
• Colonized central lines can be caused by contaminated platelets⁷

Significantly reduce your patient’s risk of transfusion-associated sepsis with The INTERCEPT^® Blood System for Platelets

1. FDA. Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use. Docket No. FDA-2006-N-0040. Fed Regist 2015;80:29842-906.